SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549-1004

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO SECTION 13 OF
THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (date of earliest event reported):  December 31, 2005

 

Ciphergen Biosystems, Inc.

(Exact name of Registrant as specified in its charter)

 

Delaware

 

000-31617

 

33-059-5156

(State or other jurisdiction of

 

[Commission File Number]

 

(I.R.S. Employer

incorporation or organization)

 

 

 

Identification Number)

 

6611 Dumbarton Circle
Fremont, CA 94555

(Address of principal executive offices)

 

(510) 505-2100

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 1.02                          Termination of Material Definitive Agreement

 

On December 30, 2005, Martin Verhoef’s employment with the Company was terminated.  Mr. Verhoef was serving as the Company’s Executive Vice President of Biosystems Operations.  Mr. Verhoef had an employment agreement with the Company, and the parties are negotiating the final terms of his departure from the Company around the basic framework provided in that employment agreement.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

CIPHERGEN BIOSYSTEMS, INC.

 

(Registrant)

 

 

 

 

 

Date:  January 6, 2006

By:

/S/ MATTHEW J. HOGAN

 

 

Matthew J. Hogan,

 

Senior Vice President and Chief Financial Officer

 

3